Loading patent…
AssigneeBoehringer Ingelheim International GmbH
InventorsMarkus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
Estimating the term…
The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
An anti-PD1 antibody molecule comprising a heavy chain variable domain comprising heavy chain CDRs comprising the amino acid sequence of SEQ ID NO:13 (hcCDR1), SEQ ID NO:14 (hcCDR2) and SEQ ID NO:15 (hcCDR3) and a light chain variable domain comprising light chain CDRs comprising the amino acid sequence of SEQ ID NO:16 (lcCDR1), SEQ ID NO:17 (lcCDR2) and SEQ ID NO:18 (lcCDR3).
An anti-PD1 antibody molecule, wherein said antibody molecule comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
An anti-PD1 antibody molecule, wherein said antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:
An anti-PD-1 antibody molecule, wherein said antibody molecule has a heavy chain, wherein the amino acid sequence of said heavy chain consists of the amino acids of SEQ ID NO:
Dependencies are inferred from the claim text.